olivLaw · US equity research
Scilex Holding Company SCLX
Biological Products, (No Diagnostic Substances) · SIC 2836 · Vertical: Biological Products, (No Diagnostic Substances) (SIC 2836)
Scilex Holding Company develops and commercializes non-opioid pain management products, led by ZTlido, a lidocaine topical system. The company faces a funding squeeze: its net loss reached $160.6 million in the first half of 2026 and management has concluded there is substantial doubt about its ability to continue as a going concern.
At the close of 04 Nov 2026, Scilex Holding Company (SCLX) stock was 1.83 USD (−1.08% on the day), with market capitalisation 15.5 m USD, beta 1.01, 52-week range 1.83–14.02 USD. Latest reported quarter (Q2 2026): revenue of 7.6 m USD (−22.8% YoY), net income of -115.0 m USD, diluted EPS -16.65 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 14.7
- oversold (≤ 30)
- Bollinger (20, 2)
- 1.63 – 3.22
- in the lower half of the band · %B 0.13 · band width 65.6%
- SMA 50 / 200
- 3.94 / 5.24
- downtrend (price < SMA50 < SMA200)
- MACD (12, 26, 9)
- -0.63 / -0.65
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | −52.1% | −1.1% | −51.0 pp | — |
| 3 months | −71.9% | −0.5% | −71.5 pp | — |
| 6 months | −69.1% | +4.4% | −73.5 pp | — |
| Year to date | −75.9% | +12.3% | −88.2 pp | — |
| 1 year | −85.1% | +13.5% | −98.6 pp | −3.8% |
| 3 years | −94.9% | +76.4% | −171.3 pp | +18.6% |
| 5 years | −99.2% | +63.7% | −162.8 pp | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q2 2026 · 30 Jun 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 14.4 m | 14.9 m | 5.0 m | 9.9 m | 10.6 m | 4.8 m | 8.6 m | 7.6 m |
| Cost of revenue | 3.8 m | 4.7 m | 1.4 m | 3.3 m | 3.3 m | 2.6 m | 4.4 m | 3.7 m |
| Gross profit | — | — | 17.7 m | 39.5 m | — | — | 25.7 m | 15.8 m |
| Research & development | 2.3 m | 2.2 m | 2.5 m | 6.2 m | 3.9 m | 8.2 m | 3.2 m | 3.3 m |
| SG&A | 29.7 m | 35.4 m | 28.1 m | 19.8 m | 188.8 m | 30.2 m | 31.0 m | 28.0 m |
| Operating income | -19.9 m | -28.4 m | -27.9 m | -20.5 m | -186.5 m | -111.1 m | -32.2 m | -29.4 m |
| Depreciation & amortisation | 1.0 m ≈ | 1.0 m | 1.0 m | 1.0 m ≈ | 1.0 m ≈ | 1.6 m | 2.9 m | 2.8 m ≈ |
| Interest expense | 576.0 k | 285.0 k | 2.5 m | 2.7 m | 2.8 m | 3.5 m | 3.8 m | 6.1 m |
| Pre-tax income | -4.4 m | -6.5 m | -26.1 m | -44.0 m | -257.8 m | -46.1 m | -45.7 m | -115.0 m |
| Income tax | 0 | -1.0 k | — | 19.0 k | 1.0 k | 6.0 k | — | 7.0 k |
| Net income | -4.4 m | -6.5 m | -26.1 m | -44.0 m | -257.8 m | -46.1 m | -45.7 m | -115.0 m |
| Diluted EPS | -0.58 | -259.54 ≈ | -2.26 | -7.42 | -22.17 | -4,909.98 ≈ | -6.28 | -16.65 |
| Operating cash flow | 5.1 m ≈ | 2.5 m | 6.0 m | 7.1 m ≈ | 8.2 m ≈ | -17.5 m | -1.1 m | -6.7 m ≈ |
| Capex | 0 ≈ | 0 | — | — | — | — | — | — |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2020 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 23.6 m | 38.0 m | 46.7 m | 56.6 m | 30.3 m |
| Revenue YoY | unavailable | unavailable | +22.9% | +21.1% | −46.5% |
| Net income | -47.5 m | -23.4 m | -114.3 m | -72.8 m | -374.1 m |
| Net income YoY | unavailable | unavailable | unavailable | unavailable | unavailable |
| Diluted EPS | -0.36 | -0.17 | -1.28 | -8.05 | -36.48 |
| Diluted EPS YoY | unavailable | unavailable | unavailable | unavailable | unavailable |
| net % | -201.7% | -61.4% | -244.6% | -128.7% | -1,236.4% |
| Free cash flow | -31.5 m | -21.3 m | -20.7 m | 19.3 m | 3.7 m |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 5.0 m USD
- Financial debt
- 83.3 m USD
- Net debt
- 78.3 m USD
- Equity
- -211.8 m USD
- Total assets
- 365.0 m USD
- Debt / equity
- unavailable
- Current ratio
- 0.08x
- ROE
- unavailable
- ROA
- -163.4%
- FCF margin
- 12.2%
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2020 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|
| Revenue | 23.6 m | 38.0 m | 46.7 m | 56.6 m | 30.3 m | SEC (XBRL)· 10 Apr 2026verified |
| Cost of revenue | 2.1 m | 10.8 m | 15.7 m | 16.7 m | 10.6 m | SEC (XBRL)· 10 Apr 2026verified |
| Gross profit | 21.4 m ≈ | 27.2 m ≈ | 31.1 m ≈ | 167.4 m | 125.8 m | SEC (XBRL)· 10 Apr 2026verified |
| Research & development | 10.0 m | 9.1 m | 12.7 m | 9.6 m | 20.7 m | SEC (XBRL)· 10 Apr 2026verified |
| SG&A | 43.0 m | 64.9 m | 119.6 m | 119.0 m | 266.9 m | SEC (XBRL)· 10 Apr 2026verified |
| Operating income | -35.3 m | -50.6 m | -105.4 m | -83.4 m | -346.0 m | SEC (XBRL)· 10 Apr 2026verified |
| Depreciation & amortisation | 3.8 m | 4.0 m | 4.1 m | 4.0 m | 4.6 m | SEC (XBRL)· 10 Apr 2026verified |
| EBITDA | -31.5 m ≈ | -46.7 m ≈ | -101.3 m ≈ | -79.4 m ≈ | -341.4 m ≈ | SEC (XBRL)· 10 Apr 2026derived |
| Interest expense | 13.1 m | 9.6 m | 1.1 m | 2.0 m | 11.5 m | SEC (XBRL)· 10 Apr 2026verified |
| Pre-tax income | -47.6 m | -23.4 m | -114.3 m | -72.8 m | -374.0 m | SEC (XBRL)· 10 Apr 2026verified |
| Income tax | -53.0 k | 4.0 k | 13.0 k | -1.0 k | 26.0 k | SEC (XBRL)· 10 Apr 2026verified |
| Net income | -47.5 m | -23.4 m | -114.3 m | -72.8 m | -374.1 m | SEC (XBRL)· 10 Apr 2026verified |
| Diluted EPS | -0.36 | -0.17 | -1.28 | -8.05 | -36.48 | SEC (XBRL)· 10 Apr 2026verified |
| Weighted average diluted shares | 132.9 k | 134.2 m | 130.3 m | 10.1 k | 11.0 k | SEC (XBRL)· 10 Apr 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Revenue − Cost of revenue; Operating income + Depreciation & amortisation.
Balance sheet · USD
| Line | 2020 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|
| Cash | 30.5 k | 2.2 m | 3.9 m | 3.3 m | 5.0 m | SEC (XBRL)· 10 Apr 2026verified |
| Receivables | — | 21.2 m | 34.6 m | 26.4 m | 15.2 m | SEC (XBRL)· 10 Apr 2026verified |
| Inventories | — | 1.4 m | 4.2 m | 2.4 m | 4.8 m | SEC (XBRL)· 10 Apr 2026verified |
| Current assets | 30.5 k | 29.6 m | 46.8 m | 41.5 m | 38.4 m | SEC (XBRL)· 10 Apr 2026verified |
| Property, plant & equipment, net | — | 772.0 k | 722.0 k | 708.0 k | 13.6 m | SEC (XBRL)· 10 Apr 2026verified |
| Goodwill | — | 13.5 m | 13.5 m | 13.5 m | 13.5 m | SEC (XBRL)· 10 Apr 2026verified |
| Intangibles (excl. goodwill) | — | 40.6 m | 36.5 m | 32.5 m | 59.1 m | SEC (XBRL)· 10 Apr 2026verified |
| Total assets | 199.5 k | 86.5 m | 101.3 m | 93.0 m | 365.0 m | SEC (XBRL)· 10 Apr 2026verified |
| Accounts payable | — | 8.5 m | 41.0 m | 52.6 m | 86.3 m | SEC (XBRL)· 10 Apr 2026verified |
| Short-term debt | — | 0 | 108.4 m | 34.9 m | 83.3 m | SEC (XBRL)· 10 Apr 2026verified |
| Long-term debt | — | 0 | — | — | — | SEC (XBRL)· 07 Mar 2023verified |
| Current liabilities | 180.8 k | 44.8 m | 250.4 m | 259.6 m | 483.7 m | SEC (XBRL)· 10 Apr 2026verified |
| Total liabilities | 180.8 k | 50.3 m | 274.2 m | 285.6 m | 576.7 m | SEC (XBRL)· 10 Apr 2026verified |
| Equity | -141.7 m | 36.2 m | -172.9 m | -192.6 m | -211.8 m | SEC (XBRL)· 10 Apr 2026verified |
| Shares outstanding at year end | — | — | — | 243.3 m | — | SEC (XBRL)· 13 Aug 2024verified |
Cash flow · USD
| Line | 2020 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|
| Operating cash flow | -31.5 m | -21.3 m | -20.7 m | 19.3 m | 3.8 m | SEC (XBRL)· 10 Apr 2026verified |
| Capex | 25.0 k | 7.0 k | 30.0 k | 0 | 133.0 k | SEC (XBRL)· 10 Apr 2026verified |
| Free cash flow | -31.5 m ≈ | -21.3 m ≈ | -20.7 m ≈ | 19.3 m ≈ | 3.7 m ≈ | SEC (XBRL)· 10 Apr 2026derived |
| Investing cash flow | -25.0 k | -2.1 m | -330.0 k | -2.7 m | 4.1 m | SEC (XBRL)· 10 Apr 2026verified |
| Financing cash flow | -19.2 m | 21.2 m | 23.6 m | -18.1 m | -5.5 m | SEC (XBRL)· 10 Apr 2026verified |
| Dividends paid | — | — | 8.7 m | 8.7 m | — | SEC (XBRL)· 31 Mar 2025verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- indicators available: 5 of at least 6
- score weight coverage: 33.3% of at least 60%
- valuation methods computed: 0 of at least 1
A scoring methodology on indicators and valuation, not investment advice.
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: 15.5 m USD
Key indicators
Coverage and freshness
Score by group
33% · Insufficient data
Estimated value range
unavailable — no valuation method could be computed
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
- DCF (discounted cash flow)unavailable · the base of the ratio is not positive
- Peers: EV/EBITDAunavailable · the base of the ratio is not positive
- Peers: P/Eunavailable · the base of the ratio is not positive
- Dividend discount (DDM)unavailable · input data missing
no valuation method could be computed
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 5 of at least 6; score weight coverage: 33.3% of at least 60%; valuation methods computed: 0 of at least 1
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | -1,469.8% | 20 (vs peers) | 19% |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | -7.3% | 0 (on a fixed band) | 25% |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | -22.2x | 0 (on a fixed band) | 19% |
| Current ratio · Balance sheet | 0.1x | 0 (on a fixed band) | 13% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | -114.6% | 0 (on a fixed band) | 25% |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet0/100 · 2/3 factors with a value
- Growth· partial0/100 · 1/2 factors with a value
- Quality· partial20/100 · 1/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partial0/100 · 1/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
Scilex Holding Company (SCLX). Latest full fiscal year: 2025; data up to 2026-06-30.
Figures computed from the financial statements: revenue 30.3 m USD in 2025; YoY growth -46.5%; net margin -1,469.8%.
Valuation cannot be computed from the available data.
Insufficient data for a verdict (indicators available: 5 of at least 6; score weight coverage: 33.3% of at least 60%; valuation methods computed: 0 of at least 1).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
No signal among the computed factors. That is not an absence of risk: factors without data were not assessed, and business risks (margins, inventory, demand) are in the source-based analysis.
What contradicts it
- Net margin: -1,469.8%
- Revenue CAGR 3Y: -7.3%
- Interest coverage: -22.2x
- Current ratio: 0.1x
- FCF yield: -114.6%
Not assessed (insufficient data or a ratio without meaning): ROIC, FCF conversion, EPS CAGR 3Y, Net debt / EBITDA, P/E (TTM), EV/EBITDA, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Biological Products, (No Diagnostic Substances) (SIC 2836) · same industry (4-digit SIC) · compared with 39 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| AMGNAmgen Inc. | 258.8 bn | 27.7 | 78.4% | 24.1% | +10.0% | +39% / +77% |
| GILDGilead Sciences, Inc. | 216.4 bn | — | -22.3% | -12.5% | +2.4% | +39% / +128% |
| MRNAModerna, Inc. | 103.2 bn | — | -39.0% | -141.4% | −39.9% | +895% / +233% |
| RVMDRevolution Medicines, Inc. | 43.2 bn | — | -93.6% | -946.8% | unavailable | +157% / +756% |
| BIIBBiogen Inc. | 37.6 bn | 108.8 | 1.9% | 3.4% | +2.2% | +40% / +9% |
| MESOMesoblast Limited | 18.5 bn | — | -19.0% | -593.9% | +191.4% | −17% / +425% |
| EXELExelixis, Inc. | 17.8 bn | 21.7 | 44.3% | 35.5% | +7.0% | +65% / +234% |
| HALOHalozyme Therapeutics, Inc. | 14.8 bn | 38.4 | 173.7% | 24.9% | +37.6% | +83% / +238% |
| KYMRKymera Therapeutics, Inc. | 11.6 bn | — | -27.3% | -341.8% | −16.7% | +101% / +556% |
| TWSTTwist Bioscience Corporation | 8.9 bn | — | -29.6% | -31.7% | +20.3% | +345% / +493% |
| SCNIScinai Immunotherapeutics Ltd. | 6.2 bn | — | -91.9% | -633.6% | +99.2% | −96% / −99% |
| CGONCG Oncology, Inc. | 6.0 bn | — | -26.4% | -3,602.7% | +254.7% | +51% / unavailable |
| TARSTarsus Pharmaceuticals, Inc. | 3.4 bn | — | -319.8% | -102.9% | +146.7% | −14% / +318% |
| DNLIDenali Therapeutics Inc. | 3.4 bn | — | -33.9% | -1,470.5% | unavailable | +8% / +13% |
| VCELVericel Corporation | 2.3 bn | 107.7 | 7.2% | 7.9% | +16.5% | +13% / +28% |
| ADMAAdma Biologics, Inc. | 2.3 bn | 13.6 | 41.9% | 35.1% | +19.6% | −45% / +183% |
| BCRXBiocryst Pharmaceuticals, Inc. | 2.1 bn | — | — | -37.4% | +94.1% | +15% / +40% |
| VIRVir Biotechnology, Inc. | 2.0 bn | — | -21.8% | -61.0% | −7.6% | +83% / +24% |
| ALVOAlvotech | 1.5 bn | 46.7 | — | 4.8% | +19.7% | −8% / −51% |
| INBXInhibrx Biosciences, Inc. | 1.3 bn | — | -1,773.6% | — | +550.0% | +3% / unavailable |
| EVAXEvaxion A | 1.2 bn | — | -100.2% | -102.4% | +125.1% | −50% / −93% |
| CADLCandel Therapeutics, Inc. | 692.5 m | — | -81.8% | — | 0.0% | +90% / +907% |
| SRZNSurrozen, Inc. | 372.0 m | — | — | -2,885.3% | −67.4% | +91% / +340% |
| AUTLAutolus Therapeutics plc | 367.3 m | — | -133.0% | -238.7% | +644.9% | −2% / −68% |
| LXEOLexeo Therapeutics, Inc. | 265.0 m | — | -46.8% | — | unavailable | −67% / −75% |
1- and 3-year price returns: for SCLX from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 3 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 5 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
In brief
Scilex Holding Company develops and commercializes non-opioid pain management products, led by ZTlido, a lidocaine topical system. The company faces a funding squeeze: its net loss reached $160.6 million in the first half of 2026 and management has concluded there is substantial doubt about its ability to continue as a going concern.
SWOT
Strengths
Weaknesses
- Heavy reliance on a single product, ZTlido, for revenue, while the other products are at an early stage 1.
- Very low liquidity at the end of the first half of 2026 and management's conclusion about substantial doubt on going concern 2.
- Recurring net losses and an accumulated deficit that limit self-funding capacity 1.
Opportunities
Threats
- Generic products could quickly erode ZTlido's market share, especially when insurer contracts are renewed 1.
- Volatility in cryptocurrency prices could reduce the value of treasury assets and require additional liquidity reserves 1.
- A clinical failure or an FDA rejection could delay or halt development of pipeline products 1.
Risks
- Going concernhigh
Management concluded there is substantial doubt about the company's ability to operate for one year after the financial statements are issued, which could force operating cutbacks if funding is not secured 12.
- Dependence on ZTlidohigh
Revenue depends largely on ZTlido, and a decline in its sales could directly affect the ability to sustain operations 1.
- Cryptocurrency exposurehigh
The cryptocurrency treasury strategy exposes the company to price volatility, regulatory uncertainty and security risks around private keys 1.
- Single-source suppliersmedium
The company relies on sole or single-source suppliers for commercial supply of some products, and a disruption could be hard to offset 1.
- Debt and restrictive covenantsmedium
The terms of the Oramed notes restrict operating and financial flexibility, and debt service could become hard to sustain 12.
Investment thesis
What would need to be true (bull case)
- If ZTlido holds its sales and ELYXYB and GLOPERBA grow faster than expected, the company could meaningfully reduce its dependence on a single product.
- Approval of SEMDEXA could open a significant market where there is no FDA-approved alternative to off-label injections.
- If financing is obtained on reasonable terms, the company could continue developing its pipeline without abandoning its strategic ambitions.
What would break the thesis
- Very low liquidity and the going concern conclusion could force large dilution or cuts to commercial programs.
- Recurring net losses and costs linked to the cryptocurrency treasury could keep consuming available capital.
- If generic products or cheaper alternatives gain share, revenue growth could fall short of the company's expectations.
What to watch
- Evolution of liquidity and any new financing or dilutionQ3 2026
- ZTlido, ELYXYB and GLOPERBA sales in the next quarterly reportQ3 2026
- Changes in federal digital-asset regulation and how the treasury strategy is classifiednext 10-K
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
The business
Scilex describes itself as a company that acquires, develops and commercializes non-opioid therapies for acute and chronic pain, focusing on indications with high unmet need. Its commercial portfolio includes ZTlido (lidocaine 1.8%) for postherpetic neuralgia, ELYXYB for acute migraine, approved by the FDA and in Canada, and GLOPERBA, a liquid oral colchicine for gout flare prophylaxis, launched in June 2024 1. The company has also adopted a cryptocurrency treasury strategy under which it intends to accumulate bitcoin and other digital assets as long-term holdings 1.
The company has also expanded beyond its product portfolio: it acquired an interest in Vivasor Holding Company in December 2025, lent 20 million USD to Quantum Scan Holdings in January 2026, and bought Datavault shares paid in bitcoin worth 150 million USD between September and November 2025 1. These transactions have substantially changed the asset profile and should be read alongside the liquidity position.
Segments
ZTlido (neuropathic pain, PHN)
ZTlido is the main commercial product, approved for neuropathic pain associated with postherpetic neuralgia. It is distributed through a direct network to wholesalers and pharmacies, and the company promotes it to primary care physicians, pain specialists and neurologists 1. The company states that more than 206 million prescription lidocaine patches were sold in the US in 2025 1.
ELYXYB and GLOPERBA
ELYXYB, launched in April 2023, is a ready-to-use oral solution for the acute treatment of migraine in adults, and GLOPERBA, launched in June 2024, is a liquid colchicine for gout flare prophylaxis 1. The company describes both as early in commercialization, and their success depends on physician acceptance and reimbursement terms 1.
Market context
The company operates in the US market for non-opioid pain therapies, where there is demand for alternatives to opioids and for treatments with a better safety profile. Gout affects, according to the company, an estimated 9.2 million people in the US 1. Epidural steroid injections are administered over 12 million times annually in the US, indicating the potential market for SEMDEXA 1.
Market access depends on reimbursement, formulary positioning and competition from generics, factors the company explicitly cites as influencing adoption of its products 1. If reimbursement remains restrictive, revenue growth could be slower than the company expects.
Trends
- Demand for non-opioid alternativestailwind
Pressure on opioid prescribing and demand for lower-risk treatments provide a supportive backdrop for products the company presents as non-opioid alternatives 1.
- Cost of financing and capital needsheadwind
The company reported rapidly depleted cash and very low liquidity, making it dependent on new financing, potentially on less favorable terms 2.
- Regulation of digital assetsmixed
The cryptocurrency treasury strategy depends on the evolution of federal regulation, including whether some assets could be classified as securities or the company could be treated as an investment company, which could substantially change its operating model 1.
- Generic competitionheadwind
The company cites generic products and cheaper alternatives as factors that could limit demand for ZTlido, ELYXYB and GLOPERBA 1.
Competitive position
Scilex competes with generic lidocaine patch makers, oral migraine treatments and conventional colchicine for gout. The documents do not name individual competitors, but they stress that cheaper alternatives and products developed by others could reduce market share 1.
In epidural steroids, SEMDEXA could compete with off-label products that are routinely administered in the US. The company argues that its patents and trade secrets could require potential competitors to run extensive preclinical and costly comparative clinical studies 1.
- Generic lidocaine patch makers
Generic products that could compete with ZTlido in the neuropathic pain prescription segment, cited by the company as a cheaper alternative 1.
- Conventional colchicine producers
Established colchicine treatments routinely used for gout could limit GLOPERBA adoption if physicians see no clear advantage 1.
- Off-label epidural corticosteroids
Off-label products routinely administered for sciatica that SEMDEXA could displace if approved 1.
- Acute migraine treatments
Other acute migraine therapies compete with ELYXYB for physician attention and formulary access 1.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
No news in our archive over the last 180 days.
SEC filings
- Current report29 Sept 2026Material agreement · Financial statements and exhibits
- Quarterly report14 Aug 2026
- Current report12 Aug 2026Material agreement · Financial statements and exhibits
- Current report22 Jul 2026Material agreement · Acquisition or disposition of assets · Financial statements and exhibits
- Current report06 Jul 2026Material agreement · Item 3.02 · Regulation FD disclosure · Financial statements and exhibits
- Current report29 Jun 2026Material agreement · Item 3.02
- Current report24 Jun 2026Shareholder vote · Financial statements and exhibits
- Quarterly report20 May 2026
- Current report11 May 2026Other events · Financial statements and exhibits
- Current report05 May 2026Material agreement · Regulation FD disclosure · Financial statements and exhibits
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / Scilex Holding Company · 10 Apr 2026
- [2] Form 10-Q, quarter ended 2026-06-30 · SEC / Scilex Holding Company · 14 Aug 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / Scilex Holding Company · 08 Oct 2024
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.